Evidence map›Paper›PMID 35633298›Full record

ArticleJournal of diabetes investigation2022

Roles of FoxM1-driven basal β-cell proliferation in maintenance of β-cell mass and glucose tolerance during adulthood.

Masato Kohata, Junta Imai, Tomohito Izumi, Junpei Yamamoto, Yohei Kawana, Akira Endo, Hiroto Sugawara, Junro Seike, Haremaru Kubo, Hiroshi Komamura and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Masato Kohata *Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Junta Imai *Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0003-4636-5905
Tomohito Izumi *Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0001-6862-9217
Junpei YamamotoDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yohei KawanaDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akira EndoDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroto SugawaraDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Junro SeikeDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Haremaru KuboDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroshi KomamuraDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshihiro SatoDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shinichiro HosakaDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuichiro MunakataDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoichiro AsaiDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shinjiro KodamaDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kei TakahashiDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Keizo KanekoDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hideki KatagiriDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0003-1093-3704
Tohoku University · JP

Funding

Japan Agency for Medical Research and Development 21gm6210002h0004 (AMED-PRIME)Japan Agency for Medical Research and Development JP21gm5010002h0005Japan Science and Technology Agency [Moonshot R&D] [Grant Number JPMJPS2023]Japan Society for the Promotion of Science 20H05694Japan Society for the Promotion of Science 20K17525Japan Society for the Promotion of Science 22H03124
6 · The paper itself

Abstract

AIMS/

introductionWhether basal β-cell proliferation during adulthood is involved in maintaining sufficient β-cell mass, and if so, the molecular mechanism(s) underlying basal β-cell proliferation remain unclear. FoxM1 is a critical transcription factor which is known to play roles in 'adaptive' β-cell proliferation, which facilitates rapid increases in β-cell mass in response to increased insulin demands. Therefore, herein we focused on the roles of β-cell FoxM1 in 'basal' β-cell proliferation under normal conditions and in the maintenance of sufficient β-cell mass as well as glucose homeostasis during adulthood. MATERIALS AND

methodsFoxM1 deficiency was induced specifically in β-cells of 8-week-old mice, followed by analyzing its short- (2 weeks) and long- (10 months) term effects on β-cell proliferation, β-cell mass, and glucose tolerance.

resultsFoxM1 deficiency suppressed β-cell proliferation at both ages, indicating critical roles of FoxM1 in basal β-cell proliferation throughout adulthood. While short-term FoxM1 deficiency affected neither β-cell mass nor glucose tolerance, long-term FoxM1 deficiency suppressed β-cell mass increases with impaired insulin secretion, thereby worsening glucose tolerance. In contrast, the insulin secretory function was not impaired in islets isolated from mice subjected to long-term β-cell FoxM1 deficiency. Therefore, β-cell mass reduction is the primary cause of impaired insulin secretion and deterioration of glucose tolerance due to long-term β-cell FoxM1 deficiency.

conclusionsBasal low-level proliferation of β-cells during adulthood is important for maintaining sufficient β-cell mass and good glucose tolerance and β-cell FoxM1 underlies this mechanism. Preserving β-cell FoxM1 activity may prevent the impairment of glucose tolerance with advancing age.

Indexed as

Forkhead Box Protein M1Insulin-Secreting CellsAnimalsCell ProliferationGlucoseInsulinMiceForkhead Box Protein M1GlucoseInsulinAdvancing ageβ-Cell mass maintenanceβ-Cell proliferation

Identifiers

PMID35633298
PMCPMC9533047
OpenAlexW4281897972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.